Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Recombination Therapeutics LLC
Profile last edited on: 12/30/21      CAGE: 850Y6      UEI: JLYJMA2WFYE3

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2018
First Award
2020
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

826 South 2nd Street Unit 2R
Philadelphia, PA 19147
   N/A
   N/A
   www.recombinationtx.com
Location: Single
Congr. District: 03
County: Philadelphia

Public Profile

A precision oncology company structured around developing next-generation precision medicines for cancer patients by targeting DDR pathways, Recombination Therapeutics (RTx) is identifying and developing alternative drug targets involved in DNA repair. Novel prodrugs that cause replicative stress and target cancer cells deficient in nucleotide metabolism and DNA end resection. These are offered as next-generation personalized medicines for BRCA-deficient cancers that increase patient survival rates and potentially reduce drug resistance.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,084,616
Phase II Dollars
$0
Total Awarded
$1,084,616

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 1 NIH $385,900
Project Title: Structure Based Design of Pol-theta inhibitors
2020 1 NIH $399,757
Project Title: Nucleotide Inhibitors as Precision Medicine in Breast Cancer
2020 1 NIH $298,959
Project Title: Next-Generation Precision Medicine for Targeting Recombination-Deficient Cancers

Key People / Management

  John Oates -- Cofounder, CEO

  Xiaojiang Chen -- Cofounder, Director of Structure Biology

  Wayne Childers -- Cofounder, Director of Medicinal Chemistry

  Richard T Pomerantz -- Cofounder, CSO

  Mercy Ramanjulu -- Senior Chemist

Company News

There are no news available.